ArticleFrontiers in oncology2026
Real-world outcomes of photodynamic therapy for HPV-associated lower genital tract lesions: a 2024-2025 gynecology follow-up cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent high-risk human papillomavirus (hrHPV) infection drives lower genital tract intraepithelial lesions. 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT) is a minimally invasive, tissue-preserving option, but real-world effectiveness remains variably reported. Methods: We analyzed de-identified standardized gynecology follow-up forms from 2024-2025 for patients treated with 5-ALA-PDT for HPV-associated lower genital tract disease. Outcomes at 3 months were genotype-specific clearance of HPV-16 and HPV-18 among baseline-positive patients and cytology normalization to negative for intraepithelial lesion or malignancy (NILM) among those with abnormal baseline ThinPrep cytology (TCT). Logistic regression explored predictors of post-treatment HPV clearance. Results: Overall, 714 patients were included; 635 (88.9%) had complete baseline and follow-up testing plus documented PDT protocol parameters (mean age 45.8 ± 12.6 years). The cervix was the most common treatment site (52.9%); median number of sessions was 4 (IQR 3-6) using 20% 5-ALA. At 3 months, HPV-16 cleared in 162/217 (74.7%), and HPV-18 cleared in 46/61 (75.4%); clearance for other HPV types was 337/566 (59.5%). Among patients with abnormal baseline TCT, 314/329 (95.4%) normalized to NILM. In multivariable analysis, a higher number of baseline HPV types predicted reduced clearance (adjusted OR 0.70, 95% CI 0.50-0.97); age <40 years was associated with clearance only in univariate analysis (OR 1.96, 95% CI 1.17-3.27) but was not significant after adjustment. Conclusions: In this retrospective routine-care cohort, 5-ALA-PDT was associated with substantial early HPV-16/18 clearance and high short-term cytologic normalization. Multitype HPV infection may be a risk factor and warrant closer surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.